Document is current
Any future updates will be listed below
-
Authors
Banerjee, Rahul https://orcid.org/0000-0003-3781-5441
Fritz, Amber R. https://orcid.org/0000-0003-1269-1091
Akhtar, Othman S.
Freeman, Ciara L. https://orcid.org/0000-0002-0662-6480
Cowan, Andrew J.
Shah, Nina
Landau, Heather J. https://orcid.org/0000-0002-3152-1189
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
Vogl, Dan T. https://orcid.org/0000-0002-2935-2566
Efebera, Yvonne A.
McCarthy, Philip L. https://orcid.org/0000-0002-9577-3879
Vesole, David H.
Mendizabal, Adam
Krishnan, Amrita Y.
Somlo, George
Stadtmauer, Edward A.
Pasquini, Marcelo C. https://orcid.org/0000-0003-1579-2293
- License Information
-
More Information
Article History
Received: 6 December 2024
Revised: 22 January 2025
Accepted: 6 February 2025
First Online: 24 February 2025
Competing interests
: RB reports: consulting, Adaptive Biotech, BMS, Caribou Biosciences, Genentech, Gilead, Janssen, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. CLF reports: honoraria/consulting for BMS, Seattle Genetics, Celgene, Abbvie, Sanofi, Incyte, Amgen, and ONK therapeutics, Janssen; research funding from BMS, Janssen and Roche/Genentech. AJC reports research funding: Janssen, BMS, Juno/Celgene, Sanofi, Regeneron, IGM biosciences, Nektar, Harpoon, Adaptive Biotechnologies, Caelum, Abbvie; advisory/consulting: Sebia, Janssen, BMS, Sanofi, HopeAI, Adaptive Biotechnologies, Abbvie. NS reports: research funding from Bristol Myers Squibb/Celgene, Janssen, bluebird bio, Sutro Biopharma, TeneoBio, Poseida, Nektar, and Precision Biosciences; consultant for GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm Therapeutics, Oncopeptides, and CSL Behring; current employee and equity holder of AstraZeneca. HJL reports: consulting, Abbvie, Immix Biopharma, Legend Biotech, Alexion, Prothena; funding: Janssen, Alexion, Protego, Prothena. SKK reports: funding: Abbvie, Celgene, Janssen, Takeda, Adaptive, Kite, AstraZeneca, Merck, Novartis, Roche, Sanofi. D.T.V. reports: consulting, Celgene, Karyopharm Therapeutics, Janssen, Takeda, GlaxoSmithKline, CSL Behring, Oncopeptides, Genentech, Sanofi; research funding, Active Biotech, Takeda. YAE reports: research funding, Takeda, Oncopeptides, Alnylam, Sanofi, GlaxoSmithKline, ORCA Therapeutics, BMS; consulting: Oncopeptides, Sanofi, Janssen Oncology, Pfizer, speaker’s bureau: Takeda, Janssen, Akcea Therapeutics. PLM reports: consulting: Beigene, BMS/Celgene/Juno, Fate Therapeutics, Glaxo Smith Klein, JnJ (Janssen), Karyopharm, Meda Consulting. D.H.V. reports: speaker’s bureau: BMS, Amgen, Takeda, Janssen, Sanofi, Karyopharm, Sanofi. AYK reports: consulting: AbbVie, Bristol Myers Squibb, GSK, JnJ, Pfizer, Regeneron, Sanofi; research funding: JnJ, Roche; speaker’s bureau: BMS, Takeda; stock options: BMS. EAS reports: consulting: Celgene, Takeda, Novartis, Teva, Janssen, Amgen, Sanofi. MCP reports: consulting: BMS; research: Novartis, Janssen, Kite. The remaining authors have no conflicts to disclose.
: All methods and study procedures. were performed in accordance with relevant guidelines and regulations. Every participating center in the BMT CTN 0702 trial obtained Institutional Review Board approval for the original study from which data were obtained for this post hoc analysis. Similarly, all study participants provided informed consent for participation in the BMT CTN 0702 trial. No identifiable information was obtained as part of this post hoc analysis.
